BIO-key International’s (NASDAQ:BKYI) “Buy” Rating Reaffirmed at Maxim Group

BIO-key International (NASDAQ:BKYI)‘s stock had its “buy” rating reissued by equities research analysts at Maxim Group in a research report issued on Thursday, December 21st. They currently have a $5.50 target price on the technology company’s stock. Maxim Group’s price target would indicate a potential upside of 163.16% from the company’s current price.

Shares of BIO-key International (BKYI) opened at $2.09 on Thursday. The stock has a market cap of $16.07, a price-to-earnings ratio of -2.15 and a beta of -0.44. BIO-key International has a one year low of $1.20 and a one year high of $3.67.

BIO-key International (NASDAQ:BKYI) last announced its earnings results on Tuesday, November 14th. The technology company reported ($0.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.11). The firm had revenue of $0.94 million during the quarter. BIO-key International had a negative return on equity of 37.54% and a negative net margin of 106.55%.

A hedge fund recently bought a new stake in BIO-key International stock. Commonwealth Equity Services Inc acquired a new stake in BIO-key International, Inc. (NASDAQ:BKYI) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 79,130 shares of the technology company’s stock, valued at approximately $226,000. Commonwealth Equity Services Inc owned about 1.22% of BIO-key International as of its most recent filing with the SEC. 2.93% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “BIO-key International’s (NASDAQ:BKYI) “Buy” Rating Reaffirmed at Maxim Group” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/14/bio-key-international-bkyi-stock-rating-reaffirmed-by-maxim-group.html.

About BIO-key International

BIO-key International, Inc develops and markets fingerprint biometric identification and identity verification technologies, cryptographic authentication-transaction security technologies, as well as related identity management and credentialing software solutions. The Company is also engaged in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, identity cards, public key infrastructure (PKI), credit card, passports, driver’s licenses, one-time password (OTP) or other form of possession or knowledge-based credentialing.

Receive News & Ratings for BIO-key International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-key International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply